NICE no for Pierre Fabre’s Braftovi by Selina McKee | Sep 8, 2020 | News | 0 Preliminary guidelines reject NHS funding for the drug for BRAF V600E mutation-positive metastatic colorectal cancer Read More
Green light for Novartis’ lung cancer combination therapy by Selina McKee | Jun 23, 2017 | News | 0 Novartis’ combination therapy Tafinlar + Mekinist has won approval from the US Food and Drug Administration to treat patients with metastatic non-small cell lung cancer (NSCLC) carrying the BRAF V600E mutation. Read More